Update information

Update information

March 2016: The wording of recommendation 1.1 has been updated in line with NICE's wording conventions.

Recommendations 1.2 and 1.3 for temozolomide for the first‑line chemotherapy treatment of malignant glioma when primary therapy (surgery and/or radiotherapy) has failed have been updated by recommendation 1.1 of NICE's technology appraisal guidance on carmustine implants and temozolomide for the treatment of newly diagnosed high‑grade glioma.